Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis

Liver International

Volumn 31, Issue 3, 2011, Pages 401-411

  Kamal, Sanaa M ^a   Ahmed, Amany ^a   Mahmoud, Sara ^a   Nabegh, Leila ^a   Gohary, Iman El ^a   Obadan, Isi ^b   Hafez, Tamer ^c   Ghoraba, Dahlia ^a   Aziz, Ahmed A ^a   Metaoei, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The American University in Cairo   (Egypt)

Author keywords

Hepatitis C; Pegylated interferon 2; Ribavirin; Therapy

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; APPETITE DISORDER; ARTICLE; CHRONIC HEPATITIS C GENOTYPE 4; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH SURVEY; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 79551545968     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02435.x     Document Type: Article

References (36)

1. World Health Organization. Hepatitis C. WHO Fact Sheet 164. Geneva, Switzerland: World Health Organization, 2000. Available at (accessed 10 September 2010).
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S21-9.
3. Angelico M, Renganathan E, Gandin C, et al. Chronic liver disease in the Alexandria Governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26: 236-43.
4. Kamal S, Nasser I. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371-83.
5. Kamal S, Madwar M, Bianchi L, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281-9.
6. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405-13.
7. Ansaldi F, Bruzzone B, Salamaso S, et al. Different seroprelavence and molecular epidemiology pattern of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-32.
8. Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 19-27.
9. Fernandez-Arcas N, Lopez-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78: 1429-35.
10. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-7.
11. Soriano V, Nunez M, Sanchez-Conde M, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antiviral Ther 2005; 10: 167-70.
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-8.
14. Kamal SM, Madwar MA, Peters T, et al. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172-4.
15. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335-9.
16. Kamal S. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29 (Suppl. 1): 39-48.
17. Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568-74.
18. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-7.
19. Kamal SM, El Tawil AA, Nakano T. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-66.
20. Kamal S, Kamary S, Shardell M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.
21. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
22. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
23. Ascione A, Luca MD, Tartaglione MT, et al. Peginterferon alphalfa-2a plus ribavirin is more effective than peginterferon alphalfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
24. Rumi M, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
25. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
27. WHO International Classification for Patient Safety. Available at (accessed 12 June 2010).
28. Cons S, Alabdulmohsin S, Draugalis J, Hays R. Reliability of an Arabic version of RAND 36-item health survey and its equivalence to the U.S English version. Med Care 1998; 36: 428-32.
29. Younossi ZM, Boparai N, Price LL, et al. Health related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-205.
30. Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press, 2007.
31. Sporea I, Danila M, Sirli R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis 2006; 15: 125-30.
32. Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol 2008; 23: 861-6.
33. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-30.
34. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-a-2b improves viral kinetics in patients with chronic hepatitis C genotypes 1. J Viral Hepat 2003; 10: 271-8.
35. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999; 31 (Suppl. 1): 250-4.
36. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-5.